Cimerli (ranibizumab-eqrn) - Amneal, Formycon, Coherus Biosci, Teva
Otulfi (ustekinumab-aauz) - Formycon, Fresenius Kabi
https://www.formycon.com/en/blog/press-release/formycon-announces-decision-on-phase-iii-trial-with-fyb206-and-provides-update-on-potential-need-to-adjust-the-valuation-of-fyb202-and-fyb201/
 
Feb 17, 2025
 
Prev Next